ASTRUM-005 | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

11,946 results for “ASTRUM-005”

Trials

View all 6416 →

Active, not recruiting

Real-world First-line Serplulimab-based Immunochemotherapy for Extensive-stage Small Cell Lung Cancer

600 participants · First posted Dec 27, 2024

Gatekeeper European 005

55 participants · First posted Sep 29, 2005

Single-dose/Multiple-doses Incremental Intravenous Injection of SY-005 （Recombinant Human Annexin A5）in Healthy Subjects

96 participants · First posted Jan 3, 2020

Drugs

View all 4886 →

AQU-005

AES-005

HGEN-005

Organizations

View all 24 →

Respira Therapeutics, Inc.

United States

Antiva Biosciences, Inc.

United States

Intas Pharmaceuticals Ltd.

India

News

View all 620 →

CHMP Recommends Serplulimab for First-Line ES-SCLC Treatment in Europe

CHMP Recommends Approval of Henlius and Intas' Serplulimab for ES-SCLC in Europe

Henlius' Serplulimab Makes History as First PD-1 Inhibitor Approved in EU for Small Cell Lung Cancer

Page 1 of 1195